Your browser doesn't support javascript.
loading
Transoral robotic surgery for recurrent cancers of the upper aerodigestive tract-Systematic review and meta-analysis.
Hardman, John; Liu, ZiWei; Brady, Grainne; Roe, Justin; Kerawala, Cyrus; Riva, Francesco; Clarke, Peter; Kim, Dae; Bhide, Shreerang; Nutting, Christopher; Harrington, Kevin; Paleri, Vinidh.
Afiliação
  • Hardman J; Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Liu Z; Institute of Cancer Research, London, UK.
  • Brady G; Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Roe J; Department of Speech and Language Therapy, The Royal Marsden NHS Foundation Trust, London, UK.
  • Kerawala C; Department of Speech and Language Therapy, The Royal Marsden NHS Foundation Trust, London, UK.
  • Riva F; Department of Surgery and Cancer, Imperial College Healthcare NHS Trust, London, UK.
  • Clarke P; Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Kim D; Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Bhide S; Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Nutting C; Department of Otolaryngology, Head and Neck Surgery, Imperial College Healthcare NHS Trust, London, UK.
  • Harrington K; Head and Neck Unit, The Royal Marsden NHS Foundation Trust, London, UK.
  • Paleri V; Institute of Cancer Research, London, UK.
Head Neck ; 42(5): 1089-1104, 2020 05.
Article em En | MEDLINE | ID: mdl-32068940
ABSTRACT

BACKGROUND:

Transoral robotic surgery (TORS) for recurrent head and neck (H&N) cancer is an emerging but relatively infrequent procedure.

METHODS:

Systematic review and meta-analysis of studies reporting survival data and functional outcomes for patients undergoing TORS for previously treated H&N cancers.

RESULTS:

Eight hundred seventy-eight records were identified, of which eight were eligible for inclusion, covering 161 cases (range 1-64). The pooled rates were as follows 2-year overall survival 73.8% (4 studies, range 70.6-75.0, 95% confidence intervals (CI) 65.4 to 81.5, [I2 0.0%, P = 1.0]); 2-year disease-free survival 74.8% (4 studies, range 56.2-92.0, 95% CI 63.3 to 84.8, [I2 36.9%, P = .2]); postoperative hemorrhage 9.3% (4 studies, range 3.3-13.3, 95% CI 4.7 to 15.1, [I2 0.0%, P = .5]).

CONCLUSIONS:

Functional and oncological outcomes are favorable, although the follow-up is limited in the literature. Larger cohorts with longer follow-up are needed for definitive conclusions to be drawn.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Procedimentos Cirúrgicos Robóticos / Neoplasias de Cabeça e Pescoço Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Procedimentos Cirúrgicos Robóticos / Neoplasias de Cabeça e Pescoço Tipo de estudo: Systematic_reviews Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article